95 related articles for article (PubMed ID: 18195113)
21. The drug-eluting stent saga.
Windecker S; Jüni P
Circulation; 2009 Feb; 119(5):653-6. PubMed ID: 19204314
[No Abstract] [Full Text] [Related]
22. The future of CART in the era of drug eluting stents: "It's not over until it's over". Counterpoint.
Tripuraneni P
Brachytherapy; 2003; 2(2):74-6. PubMed ID: 15062143
[No Abstract] [Full Text] [Related]
23. Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study).
Sheiban I; Sillano D; Biondi-Zoccai G; Chieffo A; Colombo A; Vecchio S; Margheri M; Gunn JP; Raina T; Liistro F; Bolognese L; Lee MS; Tobis J; Moretti C
J Am Coll Cardiol; 2009 Sep; 54(13):1131-6. PubMed ID: 19761932
[TBL] [Abstract][Full Text] [Related]
24. Getting real with drug-eluting stents: 5-year follow up of a real-world cohort.
Sakhuja R; Bhatt DL
Am Heart J; 2009 May; 157(5):802-4. PubMed ID: 19376303
[No Abstract] [Full Text] [Related]
25. Treatment of drug-eluting stent restenosis: a sandwich may not be the best combo.
Belardi J
Catheter Cardiovasc Interv; 2008 Apr; 71(5):599. PubMed ID: 18360848
[No Abstract] [Full Text] [Related]
26. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
[TBL] [Abstract][Full Text] [Related]
27. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET).
Agostoni P; Vermeersch P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G
Eur Heart J; 2007 Aug; 28(15):1912-3; author reply 1913. PubMed ID: 17606468
[No Abstract] [Full Text] [Related]
28. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
[TBL] [Abstract][Full Text] [Related]
29. Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy.
Aqel RA; Wells BJ; Hage FG; Tallaj J; Benza R; Pamboukian S; Rayburn B; McGiffin D; Kirklin J; Bourge R
J Heart Lung Transplant; 2008 Jun; 27(6):610-5. PubMed ID: 18503959
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up.
Roukoz H; Bavry AA; Sarkees ML; Mood GR; Kumbhani DJ; Rabbat MG; Bhatt DL
Am J Med; 2009 Jun; 122(6):581.e1-10. PubMed ID: 19486720
[TBL] [Abstract][Full Text] [Related]
31. [Late stent thrombosis thirteen months after drug-eluting stent implantation].
Sacha J; Wester A; Pluta W
Kardiol Pol; 2008 Jan; 66(1):78-80; discussion 84-5. PubMed ID: 18266191
[TBL] [Abstract][Full Text] [Related]
32. [Balloon angioplasty for the treatment of the drug-eluting stent restenosis in a patient with multivessel coronary artery disease and muscular bridge].
Pawłowski T; Kulawik T; Rzezak J
Kardiol Pol; 2008 Nov; 66(11):1229-31; discussion 1232. PubMed ID: 19105104
[No Abstract] [Full Text] [Related]
33. A critical appraisal of the safety and efficacy of drug-eluting stents.
Maluenda G; Lemesle G; Waksman R
Clin Pharmacol Ther; 2009 May; 85(5):474-80. PubMed ID: 19279567
[TBL] [Abstract][Full Text] [Related]
34. P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents.
Tiroch K; Koch W; Mehilli J; Bottiger C; Schomig A; Kastrati A
Cardiology; 2009; 112(4):263-9. PubMed ID: 18758183
[TBL] [Abstract][Full Text] [Related]
35. Safety of drug-eluting stents.
Windecker S; Jüni P
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):316-28. PubMed ID: 18414453
[TBL] [Abstract][Full Text] [Related]
36. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
Jeger RV; Schneiter S; Kaiser C; Bonetti PO; Brunner-La Rocca H; Handke M; Osswald S; Buser PT; Pfisterer ME;
Cardiology; 2009; 112(1):49-55. PubMed ID: 18580059
[TBL] [Abstract][Full Text] [Related]
37. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET.
Pfisterer M; Brunner-La Rocca HP; Rickenbacher P; Hunziker P; Mueller C; Nietlispach F; Leibundgut G; Bader F; Kaiser C;
Eur Heart J; 2009 Jan; 30(1):16-24. PubMed ID: 19033260
[TBL] [Abstract][Full Text] [Related]
38. Stent fracture following stenting of a myocardial bridge: report of two cases.
Tandar A; Whisenant BK; Michaels AD
Catheter Cardiovasc Interv; 2008 Feb; 71(2):191-6. PubMed ID: 18327836
[TBL] [Abstract][Full Text] [Related]
39. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.
Ellis SG; O'Shaughnessy CD; Martin SL; Kent K; McGarry T; Turco MA; Kereiakes DJ; Popma JJ; Friedman M; Koglin J; Stone GW;
Eur Heart J; 2008 Jul; 29(13):1625-34. PubMed ID: 18556716
[TBL] [Abstract][Full Text] [Related]
40. Stent thrombosis.
Gupta S; Gupta MM
J Assoc Physicians India; 2008 Dec; 56():969-79. PubMed ID: 19322976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
